Skip to content
10-Q

Quarterly Report

AXIM BIOTECHNOLOGIES, INC. AXIM

0001096906-23-001655

← back to feed
Filed
Aug 21, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2023 · Aug 18, 2023 233.65M sh
Shares Diluted Q2 2023 · Jun 30, 2023 226.26M sh
Shares Diluted Q2 2023 · Jun 30, 2023 220.41M sh
Shares Diluted Q2 2023 · Jun 30, 2022 154.95M sh
Shares Diluted Q2 2023 · Jun 30, 2022 151.08M sh
Current Liabilities Q2 2023 · Jun 30, 2023 $8.37M
Current Liabilities Q2 2023 · Dec 31, 2022 $3.39M
Total Liabilities Q2 2023 · Jun 30, 2023 $14M
Total Liabilities Q2 2023 · Dec 31, 2022 $9.04M
Current Assets Q2 2023 · Jun 30, 2023 $97.5K
Current Assets Q2 2023 · Dec 31, 2022 $103.98K
Total Assets Q2 2023 · Jun 30, 2023 $4.25M
Total Assets Q2 2023 · Dec 31, 2022 $4.21M
Capex Q2 2023 · Jun 30, 2022 $6K
Operating Cash Flow Q2 2023 · Jun 30, 2022 −$1.41M
Stockholders Equity restated Q2 2023 · Jun 30, 2022 −$3.42M
Stockholders Equity Q2 2023 · Mar 31, 2022 −$3.42M
Stockholders Equity Q2 2023 · Dec 31, 2021 −$2.34M
Eps Diluted Q2 2023 · Jun 30, 2022 −$0.01
Eps Diluted restated Q2 2023 · Jun 30, 2022 $0.02
Eps Basic Q2 2023 · Jun 30, 2022 −$0.01
Eps Basic restated Q2 2023 · Jun 30, 2022 $0.02
Sga Expense Q2 2023 · Jun 30, 2022 $918.71K
Sga Expense Q2 2023 · Jun 30, 2022 $1.88M
Rd Expense Q2 2023 · Jun 30, 2022 $35.17K
Rd Expense Q2 2023 · Jun 30, 2022 $79.36K
Net Income Q2 2023 · Jun 30, 2022 −$1.22M
Net Income Q2 2023 · Jun 30, 2022 −$3.31M
Operating Income Q2 2023 · Jun 30, 2022 −$1.06M
Operating Income Q2 2023 · Jun 30, 2022 −$2.17M